The study of the molecular features of medulloblastoma subgroups is also of some help for the analysis of the differential response of medulloblastoma patients to new drugs entered into the experimental therapy of these tumors, such as SMO (smoothened) inhibitors. Here, SMO is linked to medulloblastoma.